Company Will Deploy Investment to Fund Pivotal Trial

Arginox Pharmaceuticals, an emerging specialty pharmaceutical company, has announced the closing of $25 million in Series C financing. The round was led by existing investor Topspin Partners. Perseus Soros Biopharmaceutical Fund, Arginox's other institutional investor, also participated in the round. To date, the company has raised more than $42 million in venture capital, including three Small Business Innovation Research (SBIR) awards from the National Institutes of Health.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/03-01-2005/0003109348&EDATE=)